Welcome to our dedicated page for CELLECTAR BIOSC news (Ticker: CLRBZ), a resource for investors and traders seeking the latest updates and insights on CELLECTAR BIOSC stock.
The CLRBZ news page aggregates recent disclosures and media coverage related to Cellectar Biosciences, Inc., a late-stage clinical radiopharmaceutical and biotechnology company listed on NASDAQ under the symbol CLRB. Company communications describe Cellectar as focused on developing phospholipid-based targeted radiotherapeutics and radioconjugates for the treatment of cancer.
News items associated with CLRBZ and Cellectar typically cover updates on the company’s lead asset iopofosine I 131, an iodine-131 Phospholipid Drug Conjugate designed for hematologic and solid tumor cancers, as well as pipeline programs such as CLR 121125 (CLR 125), an iodine-125 Auger-emitting candidate for solid tumors, and CLR 121225 (CLR 225), an actinium-225 based candidate for pancreatic and other cancers. Coverage often includes clinical trial milestones, such as Phase 2b and Phase 1b study updates in Waldenstrom’s macroglobulinemia and pediatric high-grade glioma, and early-stage development plans in triple-negative breast cancer and pancreatic ductal adenocarcinoma.
Investors and observers can use this news feed to follow regulatory developments described by the company, including FDA designations like Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track, as well as EMA PRIME and orphan designations. Announcements may also highlight guidance from the European Medicines Agency’s Scientific Advice Working Party on potential Conditional Marketing Authorization pathways, along with information on isotope supply agreements and clinical research partnerships.
By reviewing the CLRBZ news page, readers can track how Cellectar characterizes progress across its PDC-based radiotherapeutic pipeline, including scientific presentations, preclinical data releases, financing transactions, and collaboration agreements that the company reports as supporting its oncology programs.
Cellectar Biosciences (NASDAQ:CLRB) has submitted a protocol to the FDA for a Phase 1b dose-finding study of CLR 125, an Auger-emitting radiopharmaceutical for treating triple-negative breast cancer (TNBC). The study will evaluate three different dosing regimens across 15 patients per arm, totaling 45 patients.
The trial aims to determine the recommended Phase 2 dose, assess safety and tolerability, and evaluate initial response using RECIST criteria and progression-free survival. CLR 125 showed promising preclinical results, demonstrating good tolerability and robust tumor uptake in TNBC animal models. The drug leverages the company's PDC-targeted delivery platform to deliver iodine-125 directly to cancer cell nuclei and mitochondria.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its first quarter 2025 financial results announcement and corporate update for May 13, 2025, at 8:30 AM ET. The company will host a conference call accessible via toll-free number 1-800-717-1738 (Conference ID: 53983) and webcast. A replay of the presentation will be made available in the Events section of the company's Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB) has announced plans to explore strategic alternatives to maximize stockholder value. The company, which focuses on cancer drug development, is considering various options including mergers, acquisitions, partnerships, joint ventures, and licensing arrangements.
The company has engaged Oppenheimer & Co as exclusive financial advisor for the strategic evaluation process. CEO James Caruso highlighted their key asset iopofosine I 131, along with alpha- and Auger-emitting radioconjugates (CLR 225 and CLR 125) for solid tumor treatments.
While no specific timetable has been set for the evaluation process, Cellectar emphasizes that no agreements have been reached, and there are no guarantees that the process will result in any transaction. The company will only disclose further information when deemed necessary.
Cellectar Biosciences (NASDAQ: CLRB) reported financial results for 2024 and provided corporate updates. The company achieved FDA alignment for potential accelerated approval of iopofosine I 131 for Waldenström macroglobulinemia (WM) treatment. The Phase 2 CLOVER-WaM study showed an 83.6% Overall Response Rate and 58.2% Major Response Rate.
Financial highlights include cash and equivalents of $23.3 million as of December 31, 2024, compared to $9.6 million in 2023. The company raised $44.1 million through warrant exercises in January 2024 and $19.4 million in July 2024. R&D expenses decreased to $26.1 million from $27.3 million, while G&A expenses increased to $25.6 million from $11.7 million. Net loss was $44.6 million ($1.22 per basic share).
The company plans Phase 1 solid tumor studies with two radioconjugate compounds: CLR 121125 for triple-negative breast cancer and CLR 121225 for pancreatic cancer, with an IND submission planned for first half 2025.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has announced its participation in the 37th Annual Roth Conference. The company's management team will deliver a corporate presentation on Monday, March 17, 2025, at 8:30 AM Eastern Time.
The presentation will provide an overview of the company and its operations. Interested parties can access the presentation through a webcast link, and a replay will be made available in the Events section of Cellectar's Investor Relations website.
